世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Global Sjogren’s Syndrome Therapeutics Market 2018-2022

世界のシェーグレン症候群治療市場 2018-2022年

IRTNTR23964

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
111

サマリー

この調査レポートは世界のシェーグレン症候群治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Sjogren’s Syndrome
Sjogren’s syndrome is an autoimmune disorder and the major symptoms of this disorder are dry eyes and dry mouth. The mucous membranes produce reduced tears, and moisture-secreting glands in the mouth secrete smaller amounts of saliva.
Technavio’s analysts forecast the Global Sjogren’s Syndrome Therapeutics Market to grow at a CAGR of 4.12% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the sjogren’s syndrome therapeutics market. To calculate the market size, the report considers the revenue generated from the application of sjogren’s syndrome therapeutics across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, sjogren’s syndrome therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Allergan
- Biogen
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Novartis
Market driver
- Strong pipeline
- For a full, detailed list, view our report

Market challenge
- Unwanted immunogenicity
- For a full, detailed list, view our report

Market trend
- Growing development of biologics
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: PIPELINE LANDSCAPE
- Drugs under development
PART 08: MARKET SEGMENTATION BY SUBTYPE OF SYNDROME
- Segmentation by subtype of syndrome
- Comparison by subtype of syndrome
- Primary Sjogren's syndrome - Market size and forecast 2017-2022
- Secondary Sjogren's syndrome - Market size and forecast 2017-2022
- Market opportunity by subtype of syndrome
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Growing development of biologics
- Increasing diagnostic tests and biomarkers
- Rising number of awareness programs
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Allergan
- Biogen
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Novartis
PART 16: APPENDIX
- List of abbreviations


-
-
Exhibit 01: Parent market
Exhibit 02: Global immunology treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape for Sjogren's syndrome
Exhibit 19: Molecules in pipeline for treatment of Sjogren's syndrome 2017-2018
Exhibit 20: Subtype of syndrome - Market share 2017-2022 (%)
Exhibit 21: Comparison by subtype of syndrome
Exhibit 22: Primary Sjogren's syndrome - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Primary Sjogren's syndrome - Year-over-year growth 2018-2022 (%)
Exhibit 24: Secondary Sjogren's syndrome - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Secondary Sjogren's syndrome - Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by subtype of syndrome
Exhibit 27: Customer landscape
Exhibit 28: Global - Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Recently discontinued drugs
Exhibit 41: Development of biologics
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: ALLERGAN - Overview
Exhibit 48: ALLERGAN - Business segments
Exhibit 49: ALLERGAN - Organizational developments
Exhibit 50: ALLERGAN - Geographic focus
Exhibit 51: ALLERGAN - Segment focus
Exhibit 52: ALLERGAN - Key offerings
Exhibit 53: ALLERGAN - Key customers
Exhibit 54: Biogen - Overview
Exhibit 55: Biogen - Business segments
Exhibit 56: Biogen - Organizational developments
Exhibit 57: Biogen - Geographic focus
Exhibit 58: Biogen - Key offerings
Exhibit 59: Biogen - Key customers
Exhibit 60: Bristol-Myers Squibb - Overview
Exhibit 61: Bristol-Myers Squibb - Business segments
Exhibit 62: Bristol-Myers Squibb - Organizational developments
Exhibit 63: Bristol-Myers Squibb - Geographic focus
Exhibit 64: Bristol-Myers Squibb - Key offerings
Exhibit 65: Bristol-Myers Squibb - Key customers
Exhibit 66: F. Hoffmann-La Roche - Overview
Exhibit 67: F. Hoffmann-La Roche - Business segments
Exhibit 68: F. Hoffmann-La Roche - Organizational developments
Exhibit 69: F. Hoffmann-La Roche - Geographic focus
Exhibit 70: F. Hoffmann-La Roche - Segment focus
Exhibit 71: F. Hoffmann-La Roche - Key offerings
Exhibit 72: F. Hoffmann-La Roche - Key customers
Exhibit 73: Novartis - Overview
Exhibit 74: Novartis - Business segments
Exhibit 75: Novartis - Organizational developments
Exhibit 76: Novartis - Geographic focus
Exhibit 77: Novartis - Segment focus
Exhibit 78: Novartis - Key offerings
Exhibit 79: Novartis - Key customers


-
-
-

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る